Advertisement


Jean-Charles Soria, MD, PhD, on Results of the Lux Lung 8 Clinical Trial

2015 European Cancer Congress

Advertisement

Jean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: afatinib vs erlotinib in squamous cell carcinoma of the lung.



Related Videos

Lung Cancer

Jean-Charles Soria, MD, PhD, on Results of the KEYNOTE 001 Clinical Trial

Jean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: the efficacy and safety of pembrolizumab in previously treated non-small cell lung cancer (Abstract L...

Issues in Oncology

Federico Cappuzzo, MD, and Tony Mok, MD, on Managing EGFR Resistance in Lung Cancer

Federico Cappuzzo, MD, of Istituto Toscano Tumori-Ospedale Civile Livorno, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss current strategies for...

Kidney Cancer

Toni K. Choueiri, MD, on Cabozantinib vs Everolimus in Patients With Advanced Renal Cell Carcinoma

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses results of the phase III METEOR trial in advanced renal cell carcinoma, which evaluated the efficacy of cabozan...

Skin Cancer

Shailender Bhatia, MD, on Merkel Cell Carcinoma: Final Results of a Phase II Study

Shailender Bhatia, MD, of the Fred Hutchinson Cancer Center, discusses his paper on interleukin-12 DNA and regression of Merkel cell tumors (Abstract 504).

Global Cancer Care

Milena Sant, MD, on The Latest Findings From the EUROCARE 5 Study

Milena Sant, MD, of Istituto Nazionale dei Tumori, discusses the question of whether Europe is doing better in cancer care since the 1990s (Abstract LBA1).

Advertisement

Advertisement



Advertisement